Business Wire

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

Share

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from new analyses showing long-term treatment with LIVMARLI were presented during the European Association for the Study of the Liver (EASL) Annual Congress, June 5-8, 2024, in Milan, Italy. Presentations from studies evaluating LIVMARLI® (maralixibat) oral solution in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) included:

THU-094: Clinical Benefits with Maralixibat for Patients with Alagille Syndrome are Durable Through 7 Years of Treatment: Data from the MERGE Study
Presented by Doug Mogul, MD, PhD – Mirum Pharmaceuticals, Inc., Foster City, CA, USA
An analysis of ALGS studies evaluating LIVMARLI for up to seven years of treatment were presented to demonstrate the durability of response to LIVMARLI across multiple clinical and laboratory outcomes. Data demonstrated that nearly all patients who remained on LIVMARLI for seven years experienced benefit including clinically meaningful reductions in pruritus and serum bile acids, along with improvements in height.

View the full presentation.

THU-129: Maralixibat Improves Growth in Patients with Progressive Familial Intrahepatic Cholestasis: Data from the MARCH/MARCH-ON Trials
Presented by Professor Richard J. Thompson, MD, PhD – King's College, London, UK
This analysis reported on the long-term impact of LIVMARLI on improvements in growth across a variety of PFIC types in 60 patients from the All-PFIC cohort of the MARCH/MARCH-ON clinical trials. Patients treated with LIVMARLI from the All-PFIC cohort had a statistically significant improvement in height and weight z-scores which persisted through 82 weeks of treatment.

View the full presentation.

THU-158: Improvements in Serum Bile Acid Levels are Associated with Improvements in Key Markers of Liver Health After Maralixibat Treatment in Children with Progressive Familial Intrahepatic Cholestasis: Data from the MARCH/MARCH-ON Trials
Presented by Lorenzo D’Antiga, MD - Papa Giovanni XXIII Hospital, Bergamo, Italy
This analysis aimed to assess correlations between serum bile acid (sBA) improvements and key liver parameters, including bilirubin. These data showed that reductions in sBA after treatment with LIVMARLI are correlated with reductions in bilirubin, a key marker of liver disease. These results indicate the potential for LIVMARLI to have disease modifying effects and improvements in liver health for patients with PFIC.

View the full presentation.

About LIVMARLI® (maralixibat) oral solution

LIVMARLI® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older and for progressive familial intrahepatic cholestasis (PFIC) five years of age and older.

LIVMARLI is also the only approved IBAT inhibitor approved by the European Commission for the treatment of cholestatic pruritus in patients with ALGS two months and older, and by Health Canada for the treatment of cholestatic pruritus in ALGS. For more information for U.S. residents, please visit LIVMARLI.com.

LIVMARLI has received positive opinion by CHMP in Europe for the treatment of PFIC in patients three months of age and older. A decision by the European Commission is expected by the third quarter of 2024.

LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS and PFIC. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.

IMPORTANT SAFETY INFORMATION

Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.

LIVMARLI can cause side effects, including:

Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.

US Prescribing Information
EU SmPC
Canadian Product Monograph

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. LIVMARLI has received positive opinion by CHMP in Europe for the treatment of PFIC in patients three months of age and older. A decision by the European Commission is expected by the third quarter of 2024. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

Forward-Looking Statements

This press release includes forward-looking statements pertaining to the Company’s planned participation at a scientific conference, including data presentation title and synopsis, which may include discussion of the Company’s clinical and research data regarding patient growth data while on LIVMARLI, the reliability of long-term data, and the therapeutic potential and/or commercial viability of LIVMARLI in various liver disease indications and in patient populations that are investigational only. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions including, but are not limited to, the following factors: the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Mirum’s business and prospects, adverse developments in our focused markets, or adverse developments in the U.S. or global regulatory environment or economies generally; the continued impact of COVID-19 on our business, operations and financial results; and competitive developments. Other factors that might cause such a difference include those discussed in the Company’s filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Erin Murphy
media@mirumpharma.com

Investor Contact:
Andrew McKibben
investors@mirumphama.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MultiBank Group Announces Early Access Waitlist for Pioneering $MBG Token10.7.2025 13:30:00 EEST | Press release

MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has opened the waitlist for its highly anticipated $MBG Token, ushering in a new era that bridges traditional finance and blockchain technology. The presale will take place in July 2025, with priority access now available at: token.multibankgroup.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710986556/en/ MultiBank Group Announces Early Access Waitlist for Pioneering $MBG Token Unlike typical speculative offerings, the $MBG Token stands apart as a next-generation utility token, supported by tangible assets worth $29 billion and daily trading volumes exceeding $35 billion (as of April 2025). It is designed to introduce genuine revenue streams, advanced infrastructure, and market-level trust to the digital asset space. The $MBG Token is built on MultiBank Group’s robust ecosystem, which spans four core domains: MultiBank Tra

European Commission Approves TEVIMBRA ® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma10.7.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper part of the throat located behind the nose.1 “The approval of TEVIMBRA combined with chemotherapy in Europe marks an important advancement for people with recurrent or metastatic nasopharyngeal carcinoma—a rare and challenging disease,” said Prof. Lisa Licitra, Chief of the Head and Neck Cancer Medical Oncology Department at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. “Thanks to the compelling results from the RATIONALE-309 study, we now have a powerful new treatment that not only delays disease

Alpaca Enters UK and EU Market through WealthKernel Acquisition10.7.2025 11:30:00 EEST | Press release

Alpaca, a self-clearing broker-dealer and brokerage infrastructure API, today announced its intended acquisition of WealthKernel, a wealthtech firm specializing in digital investment infrastructure and tax-advantaged products. This strategic acquisition will bring WealthKernel’s UK and EU licensed brokerage infrastructure to Alpaca, supporting their rapid global expansion to achieve its mission of opening financial services to everyone on the planet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710149866/en/ Alpaca, a self-clearing broker-dealer and brokerage infrastructure API, today announced its intended acquisition of WealthKernel, a wealthtech firm specializing in digital investment infrastructure and tax-advantaged products. "The acquisition of WealthKernel is a major step for Alpaca in becoming a truly global brokerage infrastructure. WealthKernel has gained a highly regarded reputation in the UK and EU through w

IQM Announces Major Upgrade to Resonance Quantum Cloud Platform With New Software Development Kit10.7.2025 11:09:00 EEST | Press release

IQM Quantum Computers, a global leader in building quantum computers, today announced a major upgrade to its quantum computing cloud platform, IQM Resonance, to accelerate the development of quantum algorithms with new software tools and provide end-users with a powerful new quantum system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710268218/en/ IQM Resonance The upgrade features Qrisp – a project started at Fraunhofer FOKUS – as the new default software development kit (SDK). Qrisp offers a highly powerful but easy to learn higher level programming interface for quantum developers and researchers. The Qrisp framework is and stays open source. With the new software development kit becoming the default, IQM continues to support other popular quantum programming frameworks such as Qiskit, Cirq, Cuda Quantum, and TKET ensuring flexibility for all users. IQM’s comprehensive and open approach to quantum development builds

Brightcove Unveils Its New Vision for the Future of Video Engagement, Powered by Proprietary AI and Customer Insight10.7.2025 11:00:00 EEST | Press release

Brightcove, the intelligent video engagement company, has today unveiled a bold new chapter in its evolution, signaling a renewed commitment to innovation, customer-centricity and meaningful digital experiences. Backed by new owner Bending Spoons, and incorporating its powerful proprietary AI technology, Brightcove is reimagining its platform to meet the growing demands of both Media and Enterprise customers. This marks a strategic evolution in how Brightcove approaches product development, balancing cutting-edge innovation with a relentless focus on quality of experience. The company is investing in areas that matter most to its customers, including new AI-powered features developed in-house, enhanced monetization tools, and a more intuitive user experience. Brightcove’s new direction is the result of extensive collaboration with more than 50 customers across industries, geographies, and use cases. These conversations have shaped a product strategy that is designed to meet the evolvin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye